Efficacy of reslizumab in adults with severe eosinophilic asthma with =3 exacerbations in the previous year: analyses at weeks 16 and 52 of two placebo-controlled phase 3 trials Source: International Congress 2017 – Asthma epidemiology among children and adults: from biomarkers to ACOS Year: 2017
Omalizumab in severe uncontrolled asthma: two and a half year clinical experience Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011
Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Effects of case management on hospitalisation and exacerbation rate in severe, complex COPD: A randomized controlled trial Source: Annual Congress 2011 - Exacerbations and severe chronic respiratory disease: oxygen, rehabilitation, admission to hospital and palliative care Year: 2011
Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Should the number of acute exacerbations in the previous year be used to guide treatments in COPD? Source: Eur Respir J, 57 (2) 2002122; 10.1183/13993003.02122-2020 Year: 2021
Evidence generation for the clinical impact of myCOPD in patients with mild, moderate and newly diagnosed COPD: a randomised controlled trial Source: ERJ Open Res, 6 (4) 00460-2020; 10.1183/23120541.00460-2020 Year: 2020
COPD exacerbations in the phase 3 revefenacin clinical trial program Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018
Real-world exacerbation rates in Japanese patients with COPD: results from the EXACOS observational cohort study Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations Year: 2021
Impact of patients’ setting on the prevalence of pulmonary embolism in acute exacerbation of COPD : a meta-analysis of observational studies. Source: International Congress 2017 – Pulmonary embolism Year: 2017
Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021
Four years follow-up of exacerbations in a cohort of COPD patients: 1 year interim results (EXACO study) Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects Year: 2008
STEP-UP randomized controlled trial of vapor ablation in patients with severe emphysema: 12 month results Source: International Congress 2016 – Endoscopic lung volume reduction I Year: 2016
Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one year clinical trials Source: Eur Respir J 2001; 18: Suppl. 33, 331s Year: 2001
Development of asthma in patients with eosinophilic bronchitis: prospective follow up study Source: Eur Respir J 2002; 20: Suppl. 38, 51s Year: 2002
Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece. Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020
Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) Source: Eur Respir J, 59 (1) 2100396; 10.1183/13993003.00396-2021 Year: 2022
Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018
A new treatment algorithm for acute exacerbation of IPF: a retrospective cohort study. Source: International Congress 2019 – Recent developments in intensive care unit medicine Year: 2019